Target type: biologicalprocess
The process whose specific outcome is the progression of the blood vessels of the heart over time, from its formation to the mature structure. [GOC:mtg_heart]
Coronary vasculature development is a complex and intricate process that begins during early embryonic development and continues throughout life. It involves the formation, growth, and maturation of the coronary arteries and veins, which supply blood to the heart muscle.
**Early Stages:**
* **Formation of the coronary arteries:** The coronary arteries arise from the aortic sac, a specialized structure that forms during embryonic development. The aortic sac gives rise to the ascending aorta, the coronary arteries, and the brachiocephalic artery.
* **Angiogenesis:** The process of coronary artery formation involves angiogenesis, the growth of new blood vessels from pre-existing ones. This occurs through a series of steps, including:
* **Vasculogenesis:** The formation of new blood vessels from endothelial precursor cells called angioblasts.
* **Sprouting angiogenesis:** The growth of new blood vessels from existing vessels through the formation of sprouts.
* **Intussusceptive angiogenesis:** The formation of new blood vessels by splitting pre-existing ones.
* **Formation of the coronary veins:** The coronary veins develop from the sinus venosus, a structure that connects the heart to the venous system.
**Later Stages:**
* **Growth and Remodeling:** As the heart grows and develops, the coronary arteries and veins also grow and remodel. This involves:
* **Increased branching:** The coronary vessels branch extensively to supply blood to all areas of the heart muscle.
* **Increased diameter:** The coronary vessels increase in diameter to accommodate the increasing blood flow required by the growing heart.
* **Maturation of the vessel wall:** The vessel wall thickens and strengthens to withstand the high pressures of blood flow.
* **Regulation of Blood Flow:** The coronary arteries are regulated by a complex interplay of factors, including:
* **Nerve signals:** The sympathetic and parasympathetic nervous systems influence coronary blood flow.
* **Hormonal signals:** Hormones such as adrenaline and norepinephrine can increase coronary blood flow.
* **Local factors:** Factors such as oxygen levels, carbon dioxide levels, and metabolites can influence coronary blood flow.
* **Aging and Disease:** Coronary vasculature undergoes changes with age, making it more susceptible to disease. These changes include:
* **Reduced elasticity:** The coronary arteries become less elastic, making them less able to accommodate changes in blood flow.
* **Increased stiffness:** The coronary arteries become stiffer, which can increase the risk of coronary artery disease.
* **Accumulation of plaques:** Fatty deposits (plaques) can build up in the coronary arteries, narrowing the blood vessels and increasing the risk of heart attack.
**Clinical Relevance:**
* **Coronary Artery Disease (CAD):** The most common cardiovascular disease, caused by plaque buildup in the coronary arteries, leading to restricted blood flow to the heart.
* **Congenital Heart Defects:** Abnormal development of the coronary vasculature can result in various heart defects.
* **Heart Transplantation:** Understanding coronary vasculature development is crucial for successful heart transplantation, ensuring adequate blood supply to the transplanted heart.
The development of the coronary vasculature is a continuous process that is essential for maintaining heart health throughout life. Disruptions in this process can lead to various cardiovascular diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
ATP-sensitive inward rectifier potassium channel 8 | An ATP-sensitive inward rectifier potassium channel 8 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q15842] | Homo sapiens (human) |
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 | A TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 that is encoded in the genome of human. [PRO:CNA] | Homo sapiens (human) |
Apelin receptor | An apelin receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P35414] | Homo sapiens (human) |
Bone morphogenetic protein 4 | A bone morphogenetic protein 4 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P12644] | Homo sapiens (human) |
ATP-binding cassette sub-family C member 9 | An ATP-binding cassette sub-family C member 9 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60706] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
glyburide | glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide | monochlorobenzenes; N-sulfonylurea | anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent |
pinacidil | Pinacidil: A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed) | pyridines | |
propafenone | propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidine | N-cyano-N'-(1,1-dimethylpropyl)-N''-(3-pyridinyl)guanidine: potassium channel opener | pyridines | |
staurosporine | indolocarbazole alkaloid; organic heterooctacyclic compound | apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector | |
cromakalim | Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352) | ||
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
zeneca zd 6169 | Zeneca ZD 6169: an ATP-sensitive potassium channel opener; structure given in first source | ||
cromakalim | 1-benzopyran | ||
clamikalant | clamikalant: inhibits ATP-sensitive potassium channel; structure in first source | ||
zm226600 | ZM226600: an ATP-sensitive potassium channel opener; structure in first source | anilide | |
4-oxo-6-((pyrimidin-2-ylthio)methyl)-4h-pyran-3-yl 4-nitrobenzoate | 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate: structure in first source | nitrobenzoic acid | |
fr 148083 | 5Z-7-oxozeaenol : A macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB. | aromatic ether; macrolide; phenols; secondary alcohol; secondary alpha-hydroxy ketone | antibacterial agent; antineoplastic agent; metabolite; NF-kappaB inhibitor |
way 133537 | |||
hypothemycin | hypothemycin : A macrolide that is isolated from the cultured broth of Hypomyces subiculosus and shows antifungal activity and inhibits the growth of some human cancer cells. hypothemycin: a resorcylic acid lactone antibiotic; antifungal metabolite from Hypomyces trichothecoides | aromatic ether; diol; enone; epoxide; macrolide; phenols; polyketide; secondary alpha-hydroxy ketone | antifungal agent; antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; fungal metabolite |
dorsomorphin | dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling. dorsomorphin: an AMPK inhibitor | aromatic ether; piperidines; pyrazolopyrimidine; pyridines | bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor |
apelin-13 peptide | apelin-13 : A 13 amino acid oligopeptide which is the ligand for the apelin receptor (also known as the APJ receptor). It exhibits hypotensive and neuroprotective effects, and may be a potential prognostic biomarker for acute ischemic stroke and multiple sclerosis. apelin-13 peptide: amino acid sequence in first source | oligopeptide | antihypertensive agent; autophagy inhibitor; biomarker; human metabolite; neuroprotective agent |
p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe | p-Glu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe : A thirteen-membered polypeptide consisting of p-Glu, Arg, Pro, Arg, Leu, Ser, His, Lys, Gly, Pro, Met, Pro and Phe residues joined in sequence. | polypeptide | apoptosis inhibitor; human metabolite; neuroprotective agent |
ldn 193189 | LDN 193189: inhibits bone morphogenetic protein signaling | pyrimidines | |
ml347 | ML347: an ALK2 inhibitor; structure in first source |